Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
about
Urine soluble urokinase-type plasminogen activator receptor levels correlate with proteinuria in Puumala hantavirus infectionUrinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies.Prognostic role of urokinase plasminogen activator receptor in gastric and colorectal cancer: A systematic review and meta-analysis.Imaging of human pancreatic cancer xenografts by single-photon emission computed tomography with (99m)Tc-Hynic-PEG-AE105.The CaSm (LSm1) oncogene promotes transformation, chemoresistance and metastasis of pancreatic cancer cellsRole of urokinase receptor in tumor progression and development.Tumor-associated soluble uPAR-directed endothelial cell motility and tumor angiogenesis.Impact of expression of the uPA system in sarcomas.Potential epigenetic biomarkers for the diagnosis and prognosis of pancreatic ductal adenocarcinomas.Involvement of urokinase-type plasminogen activator system in cancer: an overview.Urokinase-type plasminogen activator receptor regulates apoptotic sensitivity of colon cancer HCT116 cell line to TRAIL via JNK-p53 pathway.Current status of biomarker and targeted nanoparticle development: The precision oncology approach for pancreatic cancer therapy.Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells.Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer.The role of the hepatocyte growth factor/c-MET pathway in pancreatic stellate cell-endothelial cell interactions: antiangiogenic implications in pancreatic cancer.Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications.
P2860
Q34231973-ED172153-882B-4F1C-A53C-B21ED9EABDEEQ35678051-92D744C2-2FAB-4843-AAFC-E911C0F82DE5Q35781008-4B5E4E2E-2AF1-4709-987F-61556DD12916Q36085382-EB60693A-000B-4412-9DE7-52B0D36AC031Q36507581-46D70B30-CA1A-439E-9A65-3C630E4EA47FQ36997616-B4C4FA69-D1AC-479B-81BD-CA32E0D00BB5Q37087120-4B244812-23CA-4719-83E3-D80959DD83B8Q38111811-E087930E-207B-4EC0-B768-0757ECA8F49DQ38115619-D1DEBE0B-B153-43F1-8AFE-82061B719114Q38189275-C9F731F2-59BD-47CE-9686-42449F1D73E0Q38967029-C5A247F9-5085-4859-961E-6A3807B31A92Q39028976-C917CFB8-217E-4D95-8766-ED6672B873F7Q39424309-8B68586B-AC19-4192-A219-F3C00A9A7DE0Q40258398-38B9DCFF-64B5-4AF9-AA65-79CDFE722B3DQ53236761-F548C2CE-C775-4C8A-89E7-C2CF98F5A9B9Q54960825-9069C8D3-B3A4-4CEA-ADDC-8876BB5C22E5
P2860
Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Elevated urinary levels of uro ...... a clinically high-risk group.
@ast
Elevated urinary levels of uro ...... a clinically high-risk group.
@en
type
label
Elevated urinary levels of uro ...... a clinically high-risk group.
@ast
Elevated urinary levels of uro ...... a clinically high-risk group.
@en
prefLabel
Elevated urinary levels of uro ...... a clinically high-risk group.
@ast
Elevated urinary levels of uro ...... a clinically high-risk group.
@en
P2093
P2860
P50
P356
P1433
P1476
Elevated urinary levels of uro ...... y a clinically high-risk group
@en
P2093
Antonio Bonora
Claudio Bassi
Federico Furlan
Francesco Blasi
Giorgio Brocco
Giorgio Talamini
Stefano Barbi
P2860
P2888
P356
10.1186/1471-2407-11-448
P407
P577
2011-10-14T00:00:00Z
P5875
P6179
1026826048